Application of N4BP1 in preparation of ACT1 inhibitor drug
By using N4BP1 to regulate the expression of Act1 protein and mRNA, the specific problem of small molecule ACT1 inhibitors was solved, and effective inhibition of the IL-17 signaling pathway was achieved, which significantly reduced the expression of related disease markers, improved the therapeutic effect and reduced the Drug resistance risk.
Patent Information
- Application Number
- CN202411219434.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-11-15
AI Technical Summary
Existing small-molecule ACT1 inhibitors have specific problems, which may produce nonspecific inhibition of other similar signaling proteins, affect bioavailability, and may lead to drug resistance.
N4BP1 is used as an Act1 inhibitor to regulate the expression of Act1 protein and mRNA by knocking out or overexpressing N4BP1 full-length plasmid, truncated plasmid, and mutant plasmid, and inhibit IL-17 signaling pathway-related diseases.
Effectively inhibit the expression of Act1 protein and mRNA, reduce the activation of IL-17 signaling pathway, significantly reduce the expression of related disease markers, improve the therapeutic effect and reduce the risk of drug resistance.
Smart Images

Figure CN118949040A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to application of N4BP1 in preparing ACT1 inhibitor drugs. Background Art
[0002] ACT1 (NF-κB activator 1), also known as TRAF3IP2 (TRAF3 Interacting Protein 2), is an important signal adaptor protein. The protein contains a TRAF binding domain and a SEFIR domain (SEFIR: Similar Expression to FGF / IL-17R). The interaction of these domains with other proteins enables ACT1 to bind to a variety of signaling molecules. The conduction of all known IL-17 signaling pathways depends on the action of Act1. ACT1 activates NF-κB, MAPK and AP-1 signaling pathways by binding to the IL-17 receptor and recruiting downstream molecules such as TRAF6, thereby leading to the production of inflammatory factors. It is an important intracellular adaptor protein of IL-17 signaling. Studies have shown that the removal of Act1, a key transducer of IL-7 receptor signaling in the mouse neuroectodermal lineage, including neurons, oligodendrocytes and astrocytes, can reduce the severity of experimental autoimmune encephalomyelitis. Other studies have shown that IL-17-induced Act1 activation is a key factor in the occurrence and development of psoriasis.
[0003] Since overactivation of ACT1 is associated with a variety of inflammatory diseases and autoimmune diseases, inhibitors targeting ACT1 have become a research hotspot. The inhibitors Iguratimod and C25-140 can prevent the transduction of downstream signals, especially the activation of NF-κB and MAPK pathways, by interfering with the binding of ACT1 and TRAF6. However, the compounds may be rapidly degraded in vivo, show toxicity in certain animal models, and may affect other physiological processes that depend on TRAF6. As a small molecule inhibitor, SBI-071040 inhibits the activation of the IL-17 signaling pathway by blocking the interaction between ACT1 and the IL-17 receptor. However, the inhibitor has specificity issues and may produce nonspecific inhibition of other similar signaling proteins, affecting bioavailability and possibly leading to drug resistance. Summary of the invention
[0004] The purpose of the present invention is to solve the specificity problem of small molecule inhibitors in the prior art, which may produce non-specific inhibition on other similar signal proteins, affect bioavailability, and may cause drug resistance.
[0005] In order to achieve the above object, the present invention adopts the following technical solutions:
[0006] The use of N4BP1 as an Act1 inhibitor in the preparation of drugs for treating diseases related to IL-17 signaling pathway, Act1 protein, or the above-mentioned target gene.
[0007] Preferably, the disease includes acute mucositis, tissue infection, chronic intestinal inflammatory disease, immune encephalomyelitis, psoriasis, rheumatoid arthritis, autoimmune inflammatory connective tissue disease.
[0008] Preferably, the drug uses N4BP1 as an inhibitory target to regulate the expression of Act1 protein and mRNA.
[0009] Preferably, the technology used in the drug includes gene knockout or knockdown of N4BP1, overexpression of N4BP1 full-length plasmid, N4BP1 truncated plasmid, and mutant plasmid.
[0010] Preferably, the drug uses N4BP1 as an inhibitory target to regulate the expression of Act1 target gene and IL-17 signaling pathway target gene mRNA and protein.
[0011] Preferably, the target genes include CXCL1, CCL20, CCL2, and MMP9.
[0012] The present application also provides the use of N4BP1 as a target or predictive indicator in the preparation of products for detecting diseases related to the IL-17 signaling pathway, Act1 protein, or the above-mentioned target gene.
[0013] The present invention provides an application of preparing ACT1 inhibitor drugs based on N4BP1, using N4BP1 as an inhibitory target to regulate the expression of Act1 protein and mRNA, and the technologies used include gene knockout or knockdown of N4BP1, overexpression of N4BP1 full-length plasmid, N4BP1 truncated plasmid, and mutant plasmid. Alternatively, N4BP1 is used as an inhibitory target to regulate the expression of Act1 target gene, IL-17 signaling pathway target gene mRNA and protein, and its target genes include CXCL1, CCL20, CCL2, and MMP9. N4BP1 is used as a target for treating, preventing, and monitoring the development of related diseases, including acute mucosal or tissue infections, chronic intestinal inflammatory diseases, immune encephalomyelitis, psoriasis, rheumatoid arthritis, and autoimmune inflammatory connective tissue diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1Figures related to verifying the upregulation of Act1 protein and mRNA levels after N4BP1 knockout in one embodiment of the present invention; (A) N4BP1 was knocked out in HaCaT and NIH-3T3 cells, and WB verified the successful knockout; (B) After N4BP1 was knocked out in HaCaT and NIH-3T3 cells, Act1 was detected by WB, and the protein level of Act1 was significantly increased after N4BP1 knockout; (C) After N4BP1 was knocked out in HaCaT cells, Act1 was detected by RT-PCR, and the mRNA level of Act1 was significantly increased after N4BP1 knockout; (D) After N4BP1 was knocked out in NIH-3T3 cells, Act1 was detected by RT-PCR, and the mRNA level of Act1 was significantly increased after N4BP1 knockout; (E) IL-17 treatment slightly promoted the expression of Act1.
[0015] Figure 2 Figures related to one embodiment of the present invention verify that N4BP1 regulates Act1 independently of protein binding and degradation; (A) After overexpression of N4BP1 in 293T cells, the protein level of Act1 decreased significantly; (B) After overexpression of N4BP1 in 293T cells, the mRNA level of N4BP1 increased significantly; (C) After overexpression of N4BP1 in 293T cells, the mRNA level of Act1 decreased significantly; (D) There was no interaction between the protein levels of N4BP1 and Act1; (E) In control cells and N4BP1 knockout cells, CHX was used to inhibit protein synthesis and the dynamic changes of Act1 were detected.
[0016] Figure 3 Figures related to verifying that N4BP1 binds to Act1 mRNA through the 1-777 fragment and negatively regulates it in one embodiment of the present invention; (A) The protein domain of N4BP1; (B) The effect of overexpressing wild-type N4BP1 and different mutants on Act1 mRNA. As shown in the figure, overexpression of wild-type N4BP1 and 1-777 mutant can significantly inhibit the expression of N4BP1; (C) WB verified that FLAG-N4BP1 can be successfully immunoprecipitated, but N4BP1 was not detected; (D) After overexpressing wild-type and 1-777 mutant N4BP1, the mRNA level of N4BP1 can be significantly increased. (E) RNA immunoprecipitation shows that N4BP1 can bind to Act1 mRNA.
[0017] Figure 4Figures related to an embodiment of the present invention verify that N4BP1 down-regulates the expression of Act1 mRNA through the NYN domain; (A) After overexpression of wild-type N4BP1, D623N mutation, and D704N mutant, the expression level of N4BP1 was detected by WB; (B) After overexpression of wild-type N4BP1, D623N mutation, and D704N mutant, the expression level of N4BP1 was significantly increased by RT-PCR; (C) Overexpression of wild-type N4BP1 can significantly inhibit the expression of Act1, but after D623N and D704N mutants, the inhibitory ability was significantly weakened.
[0018] Figure 5 Figures related to verification of upregulation of protein and mRNA levels of Act1 target gene after N4BP1 knockout in one embodiment of the present invention; (A) After N4BP1 knockout in HaCaT cells, cytokines CXCL1, CCL20, CCL2, and MMP9 increased significantly, while CSF1 and CSF2 showed no significant difference; (B) After N4BP1 knockout in NIH-3T3 cells, cytokines CXCL1, CCL20, CCL2, MMP9, and S100A8 increased significantly, while S100A9 showed no significant difference; (C) In the HaCaT N4BP1 knockout cell line, IL-17-induced CXCL1 expression was significantly increased; (D) In the HaCaT N4BP1 knockout cell line, IL-17-induced CCL20 expression was significantly increased; (E) In the HaCaT N4BP1 knockout cell line, IL-17-induced CCL2 expression was significantly increased; (F) In the HaCaT N4BP1 knockout cell line, IL-17-induced CSF1 expression was significantly increased; (G) In the HaCaT N4BP1 knockout cell line, IL- IL-17 induced an insignificant increase in CSF2 expression; (H) In the NIH3T3 N4BP1 knockout cell line, IL-17 induced an insignificant increase in CXCL1 expression; (I) In the NIH3T3 N4BP1 knockout cell line, IL-17 induced an insignificant increase in CCL20 expression; (J) In the NIH3T3 N4BP1 knockout cell line, IL-17 induced an insignificant increase in CCL2 expression; (K) In the NIH3T3 N4BP1 knockout cell line, IL-17 induced an insignificant increase in MMP9 expression; (L) In the NIH3T3 N4BP1 knockout cell line, the IL-17-induced S100A8 expression did not increase significantly; (M) In the NIH3T3 N4BP1 knockout cell line, the IL-17-induced S100A9 expression did not increase significantly; (N) In HaCaT and NIH3T3 cells, after knockout of N4BP1, the expression of MMP9 and CCL2 increased significantly; (O) In HaCaT and NIH3T3 cells, after knockout of N4BP1, IL-17 treatment significantly increased the induced MMP9 expression;
[0019] Figure 6 Figures related to verifying that the Act1 inhibitor Iguratimod can partially downregulate the upregulation of Act1 target gene mRNA levels caused by N4BP1 knockout in one embodiment of the present invention. (A) Iguratimod treatment, CXCL1 expression in N4BP1 knockout cell line did not change significantly; (B) Iguratimod treatment, CCL2 expression in N4BP1 knockout cell line decreased significantly; (C) Iguratimod treatment, CCL20 expression in N4BP1 knockout cell line decreased significantly; (D) Iguratimod treatment, MMP9 expression in N4BP1 knockout cell line decreased significantly. DETAILED DESCRIPTION
[0020] The present invention is further described in detail below in conjunction with specific embodiments.
[0021] Use of N4BP1 as an Act1 inhibitor in the preparation of a drug for treating diseases related to the IL-17 signaling pathway, Act1 protein, or the above-mentioned target gene. In one embodiment, the disease includes acute mucositis, tissue infection, chronic intestinal inflammatory disease, immune encephalomyelitis, psoriasis, rheumatoid arthritis, and autoimmune inflammatory connective tissue disease.
[0022] The drug uses N4BP1 as an inhibitory target to regulate the expression of Act1 protein and mRNA; in one embodiment, the drug uses technologies including gene knockout or knockdown of N4BP1, overexpression of N4BP1 full-length plasmid, N4BP1 truncated plasmid, and mutant plasmid.
[0023] In one embodiment, the drug uses N4BP1 as an inhibitory target to regulate the expression of Act1 target gene and IL-17 signaling pathway target gene mRNA and protein.
[0024] The target genes include CXCL1, CCL20, CCL2, and MMP9.
[0025] The present application also provides the use of N4BP1 as a target or predictive indicator in the preparation of products for detecting diseases related to the IL-17 signaling pathway, Act1 protein, or the above-mentioned target gene.
[0026] The present invention first successfully constructed a stable cell line with N4BP1 knockout by transfecting N4BP1 sgRNA into HaCat and 3T3 cells. Western Blot and qPCR experiments showed that after N4BP1 knockout, the expression of Act1 protein and mRNA was significantly reduced. However, when 3T3 cells were stimulated with IL-17, the Act1 protein level in the N4BP1 knockout group increased more significantly and in a shorter time. These results suggest that N4BP1 may reduce Act1 protein expression by regulating Act1 mRNA levels.
[0027] To further explore the mechanism, the researchers overexpressed N4BP1 in 293T cells and found that both Act1 protein and mRNA levels decreased, indicating that N4BP1 can inhibit Act1 expression. IP experiments showed that N4BP1 had no direct binding relationship with Act1 protein. In addition, 3T3 cells were treated with CHX and the degradation rate of Act1 was observed. It was found that although the Act1 protein level in the N4BP1 knockout group was higher, the degradation rate was faster, further supporting that N4BP1 may regulate Act1 by affecting mRNA stability.
[0028] N4BP1 contains multiple domains related to mRNA regulation, such as the RNA binding domain KH and the RNA cleavage domain NYN. By transfecting full-length and truncated N4BP1 plasmids in 293T cells, it was found that the deletion of the NYN domain significantly weakened the downregulation of Act1 by N4BP1. RIP experiments showed that N4BP1 can bind to Act1 mRNA, especially the 1-777 truncated fragment containing the NYN domain can also bind to Act1mRNA. This indicates that the NYN domain of N4BP1 is crucial for its negative regulation of Act1.
[0029] In order to verify the role of the NYN domain in regulation, NYN domain point mutation plasmid was transfected into 293T cells, and it was found that the mutant N4BP1 had a significantly weakened ability to downregulate Act1 mRNA and protein, further proving that N4BP1 regulates the expression of Act1 mRNA through the NYN domain.
[0030] Act1 can promote the expression of target genes through multiple signaling pathways and induce inflammatory responses. Therefore, the study detected the mRNA levels of target genes in 3T3 and HaCat cells with N4BP1 knockout, and the results showed that N4BP1 knockout significantly promoted the upregulation of Act1 and its target genes. Further activation of the Act1 signaling pathway by IL-17 revealed that the protein and mRNA levels of target genes were significantly upregulated after N4BP1 knockout. The use of the Act1 inhibitor Iguratimod partially downregulated the mRNA upregulation of Act1 target genes caused by N4BP1 knockout, indicating that N4BP1 can inhibit the expression of Act1 downstream target genes better than Iguratimod.
[0031] The following is an explanation of the above content in combination with specific experiments:
[0032] Experiment 1: Cell recovery
[0033] Prepare a 37℃ water bath, immediately place the cell cryopreservation tube taken out from the -80℃ refrigerator in it, shake gently until completely dissolved, add 1mL complete culture medium (containing 10% fetal bovine serum and 1% streptomycin and penicillin) to resuspend, centrifuge at 1000r / min for 5 minutes, discard the supernatant, add fresh culture medium, pipette and mix, and drop into the culture dish. All adherent cells use complete culture medium and place in 5% CO 2 , culture in a 37°C incubator until the cells are completely attached to the wall and then the medium is replaced.
[0034] Experiment 2: Cell passaging and plating
[0035] Discard the old culture medium, rinse the cells twice with PBS, remove the PBS, add an appropriate amount of trypsin (just enough to cover the bottom of the dish), and place it in a 37°C incubator or at room temperature for 3 to 5 minutes to eliminate the stickiness between cells according to the characteristics of different cells. Then use complete culture medium to terminate the digestion. During the termination period, use a pipette to gently blow the bottom of the dish to completely detach the cells from the bottom of the dish, suck them into a centrifuge tube, and centrifuge them at 1000r / min for 3 minutes. Discard the supernatant and retain the cell pellet, then add fresh culture medium and blow it with a pipette, mix it thoroughly, take an appropriate amount and slowly add it to the cell culture dish or well plate that has been prepared with fresh culture medium, draw a cross and gently shake it so that the cells are evenly dispersed, and then place it in the incubator for culture.
[0036] Experiment 3: Cell transfection and construction of stable cell lines with N4BP1 knockout:
[0037] Before transfection, cells were evenly spread in a six-well plate at a density of 70%-80% to maintain the normal growth environment required by cells. After cells adhered to the wall, transfection was performed. The ratio of plasmid (μg) to Lipofectamine 2000 (μl) was 1:1 to 1:2. The two were mixed in a 1.5mL Eppendorf tube with a pipette tip and placed at room temperature.5 Minutes. Then add 50-100μl of low serum medium, mix well, and leave at room temperature for another 20 minutes. Replace the medium, then gently pipette the mixture into a six-well plate and gently mix. After incubation in the incubator for 6-8 hours, replace the medium. After 48-72 hours, observe the fluorescence intensity of the cell transfection, and add gradually from low to high concentrations of puromycin to select cells expressing green fluorescence. When the WT cells in the control well are completely dead and floating, replace the medium and 6-well plate to maintain cell growth. After the cells are full, they are frozen and identified by Western Blot.
[0038] Experiment 4: Western Blot
[0039] Discard the culture medium, wash the cells once, digest the cells for 2 minutes, blow the culture medium into a centrifuge tube, centrifuge, and discard the supernatant. Add an appropriate amount of protein lysis buffer mixed with PMSF (RIPA:PMSF=100:1), place the EP tube on ice, and shake at 200 rpm on a shaker for 30 minutes. Centrifuge at 12,000 rpm for 15 minutes, transfer the supernatant to a new EP tube, mix with protein loading buffer, and place in a metal bath at 95°C for 5 minutes. Make gel. Add protein marker and protein extract. Use 80V voltage in the concentrated gel. When the marker is separated enough, adjust the voltage to 120V so that Loading runs to the bottom. The transfer conditions are 300mA, 1h, so that the protein bands on the gel are transferred to the NC membrane. The membrane is placed in 5% skim milk for 2h. Incubate the primary antibody in a refrigerator at 4°C overnight. Recover the primary antibody, wash away the residual primary antibody on the surface of the NC membrane with the prepared TBST, incubate with the corresponding secondary antibody on a shaker at room temperature for 2 hours, wash away the secondary antibody, and develop.
[0040] Experiment 5: qPCR
[0041] Add the sample to TRIZOL and mix thoroughly to rupture the cell membrane and release RNA. Add chloroform, shake vigorously, and let stand to separate the phases. The aqueous phase (upper layer) contains RNA. Carefully pipette the aqueous phase into a new tube, add an equal volume of isopropanol, mix gently, and let stand to precipitate the RNA. Collect the RNA precipitate by centrifugation and wash with 75% ethanol to remove impurities and salt. After removing the ethanol, add an appropriate amount of RNase-free water to dissolve the RNA, and the concentration and purity can be determined by a spectrophotometer. Follow the process in the reagent manual, first remove the genomic DNA, and then reverse transcribe to obtain cDNA. Add cDNA template, specific primers, qPCR reagents, and RNase-free water to the PCR plate or tube. Set up the qPCR program, obtain the experimental results, and analyze the expression level of the target gene by the CT value (cycle threshold), usually relative to the internal reference gene.
[0042] Experiment 6: CO-IP
[0043] Discard the culture medium, wash the cells once with PBS, discard the PBS (make sure the cells are not washed away), add RIPA lysis buffer without SDS and scrape the cells with a cell scraper, move to the EP tube and blow the cells. Place the EP tube on ice and shake for 30 minutes to lyse the cells, centrifuge at 4℃, 12000 rpm for 15 minutes. Take the supernatant. Take part of the supernatant as input, add protein loading buffer, boil at 95℃ in a metal bath for 10 minutes, and store at -20℃ for later use. Add ProteinA to the remaining supernatant and flick to mix, rotate at 4℃ for 2 hours. Take the supernatant after centrifugation. Divide the pre-clarified supernatant into 2 parts, add control IgG or target antibody respectively. Rotate at 4℃ overnight. The next day, add proteinA and rotate at 4℃ for 2 hours; discard the supernatant after centrifugation. Wash 3 times with RIPA lysis buffer (without SDS), centrifuge and discard the supernatant after each wash; for the last wash, discard the supernatant, add 50μl SDS, mix, and boil for 10 minutes. Detection was performed using a Western-blot detection instrument.
[0044] Experiment 7: RIP
[0045] After collecting the cells, resuspend them twice with pre-cooled PBS to remove the culture supernatant, centrifuge, resuspend them with PBS, add formaldehyde and incubate them at room temperature with slow rotation for 10 minutes. Add glycine solution and incubate at room temperature for 5 minutes. Collect the cells by centrifugation, then wash them twice with ice-cold PBS, resuspend them with RIPA lysis buffer, and then lyse the cells by three rounds of ultrasonication. Take out 50μl of the above solution as input, add Trizol and place it at -80℃. Then add 50μl of proteinA, rotate and mix at 4℃ for 2-4h; take another 40μl of proteinA, add 500μl of RIPA (without SDS) lysis buffer and 3μg of antibody, rotate and mix at 4℃ for 2-4h. Incubate the protein solution at 4℃, 12000rpm, 15min, keep the supernatant; incubate the solution in proteinA at 4℃, 800rpm, 5min, and discard the supernatant. Mix the two, rotate and mix overnight at 4℃. Discard the supernatant again, add RIPA lysis buffer and resuspend, and do this 3 times. Finally, discard the supernatant completely. The beads containing the immunoprecipitated sample were collected and resuspended in a cross-linking agent. The sample (resuspended beads) was incubated at 70°C for 45 minutes to reverse the cross-linking and Trizol was added. The solution with RIPA was used to extract protein for Western-blot experiments. The solution with Trizol was used to extract RNA and then reverse transcribed for PCR experiments.
[0046] According to the above experimental steps, the experimental results obtained are as follows:
[0047] (1) N4BP1 and Vec sgRNAs were transfected into HaCat and 3T3 cells, and a stable cell line with N4BP1 knockout was successfully constructed.
[0048] (2) The expression levels of Act1 protein and mRNA were detected by Western Blot and qPCR experiments. Figure 1 As shown in the figure, the expression of Act1 protein and mRNA was significantly reduced after N4BP1 knockout. In addition, after 3T3 cells were stimulated with IL-17, the Act1 protein in the N4BP1 knockout group increased to a greater extent and took a shorter time to increase compared with the sgV group.
[0049] (3) To further explore the specific mechanism by which N4BP1 knockout inhibits Act1 expression, 293T cells were transfected with N4BP1 overexpression plasmid. The experimental results showed that after transfection with N4BP1, the levels of Act1 protein and mRNA decreased, indicating that N4BP1 can inhibit the expression levels of Act1 protein and mRNA.
[0050] (4) IP experimental results showed that N4BP1 did not directly bind to Act1 protein. 3T3 control group and N4BP1 knockout group cells were treated with CHX, and the degradation rate of Act1 was detected by Western Blot. Figure 2 Although the level of Act1 protein was higher in the N4BP1 knockout group, the degradation rate was faster. The above results suggest that N4BP1 may reduce Act1 protein through mRNA level.
[0051] (5) N4BP1 has multiple domains related to mRNA regulation, including the RNA binding domain KH and the RNA cleavage domain NYN. In order to clarify which domain in N4BP1 plays an important role in regulating Act1, it can be determined by transfecting the full-length and multiple truncated plasmids of N4BP1 into 293T cells. The experimental results showed that the loss of the NYN domain could significantly weaken the level of Act1 protein down-regulated by N4BP1. Furthermore, the RIP experiment showed that N4BP1 can bind well to Act1 mRNA. In addition, the experimental results showed that the 1-777 truncated fragment containing the NYN domain can also bind to Act1 mRNA. The above experimental results show that the negative regulation of Act1 by N4BP1 is related to its 1-777 fragment (see Figure 3 ).
[0052] (6) To further verify whether N4BP1 regulates Act1 mRNA through the NYN domain, NYN domain point mutation plasmid was transfected into 293T cells. Western Blot and qPCR experimental results showed that the downregulation of Act1 mRNA and protein levels by N4BP1 with NYN domain mutation was significantly weakened. This result indicates that N4BP1 downregulates Act1 mRNA expression through the NYN domain (see Figure 4 ).
[0053] (7) Studies have shown that Act1 can promote the expression of target genes by regulating multiple signaling pathways, leading to inflammatory responses. Therefore, the mRNA levels of target genes were detected in 3T3 and HaCat cells with N4BP1 knockout. The experimental results showed that after N4BP1 knockout, it can promote the upregulation of Act1 protein and upregulate the expression level of Act1 target genes. At the same time, IL-17 was used to further activate the Act1 signaling pathway. The experimental results showed that after N4BP1 knockout, the protein and mRNA levels of the gene were significantly upregulated ( Figure 5 In addition, the Act1 inhibitor Iguratimod can partially downregulate the upregulation of Act1 target gene mRNA levels caused by N4BP1 knockout ( Figure 6 ). Therefore, according to the experimental results, the use of N4BP1 as an Act1 inhibitor proposed in the present invention can more significantly inhibit the expression of Act1 downstream target genes compared to Iguratimod.
[0054] In summary, the present invention provides an application of preparing ACT1 inhibitor drugs based on N4BP1, using N4BP1 as an inhibitory target to regulate the expression of Act1 protein and mRNA, and the technologies used include gene knockout or knockdown of N4BP1, overexpression of N4BP1 full-length plasmid, N4BP1 truncated plasmid, and mutant plasmid. Alternatively, N4BP1 is used as an inhibitory target to regulate the expression of Act1 target gene, IL-17 signaling pathway target gene mRNA and protein, and its target genes include CXCL1, CCL20, CCL2, and MMP9. And N4BP1 is used as a target for treating, preventing, and monitoring the development of related diseases, including acute mucosal or tissue infections, chronic intestinal inflammatory diseases, immune encephalomyelitis, psoriasis, rheumatoid arthritis, and autoimmune inflammatory connective tissue diseases.
Claims
1. Application of N4BP1 in the preparation of Act1 inhibitors.
2. Use of N4BP1 as an Act1 inhibitor in the preparation of drugs for treating diseases related to IL-17 signaling pathway, Act1 protein, or the above-mentioned target gene.
3. The use of N4BP1 as an Act1 inhibitor according to claim 1 in the preparation of a drug for treating diseases related to IL-17 signaling pathway, Act1 protein, or the above-mentioned target gene, characterized in that: The diseases include acute mucositis, tissue infection, chronic intestinal inflammatory disease, immune encephalomyelitis, psoriasis, rheumatoid arthritis, and autoimmune inflammatory connective tissue disease.
4. The use of N4BP1 as an Act1 inhibitor according to claim 1 in the preparation of a drug for treating diseases related to IL-17 signaling pathway, Act1 protein, or the above-mentioned target gene, characterized in that: The drug uses N4BP1 as an inhibitory target to regulate the expression of Act1 protein and mRNA.
5. The use of N4BP1 as an Act1 inhibitor according to claim 3 in the preparation of a drug for treating diseases related to IL-17 signaling pathway, Act1 protein, or the above-mentioned target gene, characterized in that: The technologies used in the drug include gene knockout or knockdown of N4BP1, overexpression of N4BP1 full-length plasmid, N4BP1 truncated plasmid, and mutant plasmid.
6. The use of N4BP1 as an Act1 inhibitor according to claim 1 in the preparation of a drug for treating diseases related to IL-17 signaling pathway, Act1 protein, or the above target gene, characterized in that: The drug uses N4BP1 as an inhibitory target to regulate the expression of Act1 target gene and IL-17 signaling pathway target gene mRNA and protein.
7. Use of N4BP1 as an Act1 inhibitor according to claim 5 in the preparation of a drug for treating diseases related to IL-17 signaling pathway, Act1 protein, or the above-mentioned target gene, characterized in that: The target genes include CXCL1, CCL20, CCL2, and MMP9.
8. Use of N4BP1 as a target or predictive indicator in the preparation of products for detecting diseases related to IL-17 signaling pathway, Act1 protein, or the target gene as described in claim 6.
